PE20030731A1 - Sales estables del acido o-acetilsalicilico con aminoacidos basicos ii - Google Patents
Sales estables del acido o-acetilsalicilico con aminoacidos basicos iiInfo
- Publication number
- PE20030731A1 PE20030731A1 PE2003000052A PE2003000052A PE20030731A1 PE 20030731 A1 PE20030731 A1 PE 20030731A1 PE 2003000052 A PE2003000052 A PE 2003000052A PE 2003000052 A PE2003000052 A PE 2003000052A PE 20030731 A1 PE20030731 A1 PE 20030731A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- basic amino
- acid
- amino acids
- refers
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 2
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 abstract 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 229960003104 ornithine Drugs 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 235000010356 sorbitol Nutrition 0.000 abstract 1
- 239000000811 xylitol Substances 0.000 abstract 1
- 235000010447 xylitol Nutrition 0.000 abstract 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 abstract 1
- 229960002675 xylitol Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
Abstract
SE REFIERE A UNA COMPOSICION QUE COMPRENDE: i)UNA SAL DE ACIDO O-ACETILSALICILICO; ii)UN AMINOACIDO BASICO, TAL COMO LISINA, ARGININA, HISTIDINA, ORNITINA O ACIDO DIAMINOBUTIRICO, QUE PRESENTA UN TAMANO MEDIO DE GRANO SUPERIOR A UN TAMANO DE GRANO DE 160 µm Y UNA PROPORCION DE MAS DE 60% DE LAS PARTICULAS CON UN TAMANO DE GRANO EN UN INTERVALO DE 100 µm A 200 µm; Y, iii)UN AGENTE DE FLUENCIA TAL COMO UNO O MAS SACARIDOS, SELECCIONADOS DE MANITOL, SORBITOL, XILITOL Y LACTOSA ASI COMO SUS MEZCLAS. DONDE LA COMPOSICION ESTA GRANULADA EN SECO, PREFERIBLEMENTE COMPACTADA ENTRE RODILLOS. SE REFIERE TAMBIEN A MEDICAMENTOS QUE CONTIENEN DICHA COMPOSICION Y AL USO DE LA MISMA EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES CARDIACAS ISQUEMICAS, APOPLEJIA CEREBRAL, ANGINA DE PECHO, INFARTO DE MIOCARDIO Y SIMILARES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10202019A DE10202019A1 (de) | 2002-01-18 | 2002-01-18 | Stabile Salze von o-Acetylsalicylsäure mit basischen Aminosäuren II |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030731A1 true PE20030731A1 (es) | 2003-09-22 |
Family
ID=7712593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000052A PE20030731A1 (es) | 2002-01-18 | 2003-01-17 | Sales estables del acido o-acetilsalicilico con aminoacidos basicos ii |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20050171070A1 (es) |
| EP (1) | EP1469835B1 (es) |
| JP (1) | JP2005519892A (es) |
| KR (1) | KR20040079936A (es) |
| CN (1) | CN1298314C (es) |
| AR (1) | AR038298A1 (es) |
| AT (1) | ATE378040T1 (es) |
| AU (1) | AU2003235700B2 (es) |
| BR (1) | BR0307009A (es) |
| CA (1) | CA2473893A1 (es) |
| CO (1) | CO5611102A2 (es) |
| CU (1) | CU20040161A7 (es) |
| DE (2) | DE10202019A1 (es) |
| EC (1) | ECSP045192A (es) |
| ES (1) | ES2297166T3 (es) |
| GT (1) | GT200300004A (es) |
| HN (1) | HN2003000015A (es) |
| HR (1) | HRP20040742B1 (es) |
| IL (1) | IL162881A0 (es) |
| MX (1) | MXPA04006832A (es) |
| NO (1) | NO20043404L (es) |
| NZ (1) | NZ534128A (es) |
| PE (1) | PE20030731A1 (es) |
| PL (1) | PL370197A1 (es) |
| RS (1) | RS63804A (es) |
| SV (1) | SV2004001457A (es) |
| TW (1) | TWI265810B (es) |
| UY (1) | UY27612A1 (es) |
| WO (1) | WO2003059323A2 (es) |
| ZA (1) | ZA200405533B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004025535A1 (de) * | 2004-05-25 | 2005-12-22 | Bayer Healthcare Ag | Kombination von Salzen der o-Acetylsalicylsäure und Alpha-Glucosidase-Inhibitoren |
| DE102005025283A1 (de) * | 2005-06-02 | 2006-12-07 | Bayer Healthcare Ag | Stabiler Wirkstoffkomplex von Salzen der o-Acetylsalicylsäure mit basischen Aminosäuren und Glycin |
| DE102005049293A1 (de) * | 2005-10-15 | 2007-04-26 | Bayer Healthcare Ag | Kombinationspräparate von Salzen oder o-Acetylsalicylsäure |
| DE102008004386A1 (de) | 2008-01-14 | 2009-07-23 | Activaero Gmbh | Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen |
| JP5309977B2 (ja) * | 2008-12-26 | 2013-10-09 | ライオン株式会社 | チュアブル錠 |
| US8173625B2 (en) | 2009-05-08 | 2012-05-08 | Theaprin Pharmaceuticals Inc. | Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine |
| CA2766048A1 (en) * | 2009-06-25 | 2010-12-29 | Tetra, Sia | Novel acetylsalicylic acid salts |
| JP5563835B2 (ja) * | 2010-01-15 | 2014-07-30 | 全星薬品工業株式会社 | アスピリン錠剤の製造方法 |
| ITMI20121144A1 (it) * | 2012-06-28 | 2013-12-29 | Dipharma Francis Srl | Procedimento per la preparazione di un sale di un farmaco antinfiammatorio non steroideo |
| US10882811B2 (en) | 2016-12-23 | 2021-01-05 | Aspiair Gmbh | Synthesis of lysine acetylsalicylate glycine particles |
| RU2738831C1 (ru) * | 2020-03-03 | 2020-12-17 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) | Способ консервативного лечения невралгии тройничного нерва |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5610110A (en) * | 1979-07-06 | 1981-02-02 | Green Cross Corp:The | Acetyl salicylate salt preparation for injection |
| FR2611501B1 (fr) * | 1987-03-04 | 1991-12-06 | Corbiere Jerome | Nouvelles compositions pharmaceutiques pour la voie buccale a base d'acetylsalielylate de lysine et leur procede d'obtention |
| DE10034802A1 (de) * | 2000-07-18 | 2002-01-31 | Bayer Ag | Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren |
-
2002
- 2002-01-18 DE DE10202019A patent/DE10202019A1/de not_active Withdrawn
-
2003
- 2003-01-07 AT AT03729426T patent/ATE378040T1/de not_active IP Right Cessation
- 2003-01-07 IL IL16288103A patent/IL162881A0/xx unknown
- 2003-01-07 PL PL03370197A patent/PL370197A1/xx not_active Application Discontinuation
- 2003-01-07 CA CA002473893A patent/CA2473893A1/en not_active Abandoned
- 2003-01-07 AU AU2003235700A patent/AU2003235700B2/en not_active Ceased
- 2003-01-07 ES ES03729426T patent/ES2297166T3/es not_active Expired - Lifetime
- 2003-01-07 DE DE50308596T patent/DE50308596D1/de not_active Expired - Lifetime
- 2003-01-07 RS YU63804A patent/RS63804A/sr unknown
- 2003-01-07 JP JP2003559486A patent/JP2005519892A/ja active Pending
- 2003-01-07 MX MXPA04006832A patent/MXPA04006832A/es active IP Right Grant
- 2003-01-07 KR KR10-2004-7011078A patent/KR20040079936A/ko not_active Ceased
- 2003-01-07 EP EP03729426A patent/EP1469835B1/de not_active Expired - Lifetime
- 2003-01-07 BR BR0307009-3A patent/BR0307009A/pt not_active IP Right Cessation
- 2003-01-07 CN CNB038064154A patent/CN1298314C/zh not_active Expired - Fee Related
- 2003-01-07 WO PCT/EP2003/000059 patent/WO2003059323A2/de not_active Ceased
- 2003-01-07 NZ NZ534128A patent/NZ534128A/en not_active IP Right Cessation
- 2003-01-07 US US10/501,677 patent/US20050171070A1/en not_active Abandoned
- 2003-01-07 HR HR20040742A patent/HRP20040742B1/xx not_active IP Right Cessation
- 2003-01-14 GT GT200300004A patent/GT200300004A/es unknown
- 2003-01-15 UY UY27612A patent/UY27612A1/es not_active Application Discontinuation
- 2003-01-16 AR ARP030100121A patent/AR038298A1/es not_active Application Discontinuation
- 2003-01-17 TW TW092100932A patent/TWI265810B/zh not_active IP Right Cessation
- 2003-01-17 SV SV2003001457A patent/SV2004001457A/es unknown
- 2003-01-17 HN HN2003000015A patent/HN2003000015A/es unknown
- 2003-01-17 PE PE2003000052A patent/PE20030731A1/es not_active Application Discontinuation
-
2004
- 2004-07-13 ZA ZA200405533A patent/ZA200405533B/en unknown
- 2004-07-15 EC EC2004005192A patent/ECSP045192A/es unknown
- 2004-07-19 CU CU20040161A patent/CU20040161A7/es unknown
- 2004-08-16 NO NO20043404A patent/NO20043404L/no not_active Application Discontinuation
- 2004-08-17 CO CO04079945A patent/CO5611102A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Levin et al. | Next generation matrix metalloproteinase inhibitors—Novel strategies bring new prospects | |
| PE20030731A1 (es) | Sales estables del acido o-acetilsalicilico con aminoacidos basicos ii | |
| Paschen et al. | Polyamine changes in reversible cerebral ischemia | |
| ES2176355T3 (es) | Formulaciones de aerosol de peptidos y proteinas. | |
| AR026064A1 (es) | Compuestos de oxabispidina, formulacion farmaceutica, uso de estos compuestos para la manufactura de medicamentos, proceso para la preparacion de estos compuestos, e intermediarios. | |
| AR006122A1 (es) | Una composicion farmaceutica, un compuesto de (4-oxi-3-(aril)fenil)-azarilo o-arilcarboniloxi, en la forma libre o de sal de adicion de acidofarmaceuticamente aceptable comprendida en dicha composicion, un proceso para preparar dicho compuesto y compuestos intermediarios empleados en dicho proceso | |
| ECSP941104A (es) | Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| DE502005008880D1 (de) | Liposomale zusammensetzung einen wirkstoff zur relaxierung glatter muskulatur enthaltend, die herstellung dieser zusammensetzung und deren therapeutische verwendung | |
| PE66998A1 (es) | Composiciones para el tratamiento con una dosis diaria para enfermedades producidas por la ciclooxigenasa-2 | |
| BR0008405A (pt) | Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa | |
| PE20061046A1 (es) | Composicion farmaceutica que comprende telmisartan y amlodipino | |
| SE0200979D0 (sv) | New compounds | |
| CA2445145A1 (en) | Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes | |
| AR030305A1 (es) | Composicion que comprende sales de acido o-acetilsalicilico con aminoacidos basicos, un procedimiento para su preparacion, uso de dicha composicion para la manufactura de un medicamento | |
| AR027533A1 (es) | Derivados de acido malonico, procesos para su preparacion, su uso y composiciones farmaceuticas que los contienen | |
| HUP0202807A2 (hu) | Az ischemia kezelésére szolgáló vegyületek | |
| ES2165936T3 (es) | Procedimiento para la fabricacion de una formulacion terapeutica liposomal seca y solida, dispersable en agua, de administracion oral. | |
| HUP0002932A2 (hu) | HIV-proteáz inhibitorokat tartalmazó gyógyszerkészítmények | |
| CY1107849T1 (el) | Η χρηση παραγωγων φουμαρικου οξεος για θεραπεια καρδιακης ανεπαρκειας και ασθματος | |
| AR038144A1 (es) | Agonistas del receptor 2 del factor liberador de la corticotropina | |
| CO5480297A1 (es) | Composiciones farmaceuticas en forma de granulado soluble que contienen fosfomycin tromethamol y un estabilizante | |
| NO20082181L (no) | Formuleringer av Fispemifen | |
| SE9401005L (sv) | Farmaceutisk komposition med analgetisk aktivitet | |
| BRPI0517305A (pt) | formulação liofilizada estabilizada para derivados de cefalosporina | |
| PE20001496A1 (es) | Formulacion de liberacion controlada para el tratamiento de epoc |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |